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Administration of long-acting anthelmintics to pregnant ewes prior to lambing is a common practice in
New Zealand. Today, most of these products contain macrocyclic lactone (ML) actives, which because of
their lipophilic nature, are detectable in the milk of treated animals and in the plasma of their suckling
offspring. This study was conducted to conﬁrm the transfer of ML actives to lambs in the ewe's milk, and
to assess whether this could result in selection for ML resistant nematodes in the lamb. Ninety, twin
bearing Romney ewes were treated before lambing with a long-acting injectable formulation of mox-
idectin, a 100-day controlled release capsule (CRC) containing abamectin and albendazole, or remained
untreated. After lambing, seven ewes from each treatment group were selected for uniformity of lambing
date and, along with their twin lambs, relocated indoors. At intervals, all ewes and lambs were bled, and
samples of ewe's milk were collected, for determination of drug concentrations. Commencing 4 weeks
after birth all lambs were dosed weekly with 250 infective larvae (L3) of either an ML-susceptible or
eresistant isolate of Teladorsagia circumcinta. At 12 weeks of age all lambs were slaughtered and their
abomasa recovered for worm counts. Moxidectin was detected in the plasma of moxidectin-treated ewes
until about 50 days after treatment and in their lambs until about day 60. Abamectin was detected in the
plasma of CRC-treated ewes until the last sample on day 80 and in the plasma of their lambs until about
day 60. Both actives were detectable in milk of treated ewes until day 80 after treatment. Establishment
of resistant L3 was not different between the treatment groups but treatment of ewes with moxidectin
reduced establishment of susceptible L3 by 70%, conﬁrming the potential of drug transfer in milk to
screen for ML-resistance in the suckling lamb.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The administration of anthelmintics to adult ewes in the weeks
pre- or post-lambing has been a common practice amongst sheep
farmers in New Zealand for many years (Brunsdon et al., 1983;
Lawrence et al., 2007) and the practice is also common in other
countries (Sargison et al., 2012; Dever and Kahn, 2015). The po-
tential of treating ewes at this time to accelerate the development
of anthelmintic resistance has been recognized for almost as long
(Dash et al., 1985; Michel, 1985). Considering this practice as high
risk for selecting anthelmintic resistance in New Zealand was
supported by results of a modelling study (Leathwick et al., 1995), a(D.M. Leathwick).
Ltd on behalf of Australian Society freplicated ﬁeld trial (Leathwick et al., 2006) and a national survey
of resistance and associated management factors (Lawrence et al.,
2006). Although another localised survey in New Zealand failed
to ﬁnd an association between long-acting ewe treatments and
ivermectin resistance (Hughes et al., 2007) this does not negate the
conclusion that treatment of ewes pre-lambing, especially with
long-acting anthelmintics, is a high risk practice for the develop-
ment of resistance (Leathwick and Besier, 2014). Today, farmer's
preferred choices for treatment of ewes pre-lambing are long-
acting products such as CRC and macrocyclic lactone products
with persistent activity.
Two products commonly used as pre-lambing treatments for
ewes in New Zealand today are moxidectin injection and a CRC
continuously releasing low doses of both abamectin and albenda-
zole over approximately 100 days. The long persistency associated
with moxidectin, (Carceles et al., 2001; Imperiale et al., 2004), andor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Summary of the sampling/dosing regimes for ewes and lambs in the trial where
L¼measure liveweight, B¼ bleed from jugular vein,M¼milk sample, P¼ dosewith
250 L3 of Teladorsagia circumcinta, F ¼ sample for faecal nematode egg count, and
S ¼ slaughter for recovery of abomasa.
Days post mean lambing date Days post treatment Ewes Lambs
0 B
0 10
7 17 B
14 24 L L
17 27 BM LB
29 39 BLM LBP
35 45 L LP
43 53 LBM LBP
49 59 L LP
56 66 LBM LBPF
63 73 L LPF
70 80 LBM LBPF
74 84 BF
78 88 BF
80 90 S
84 94 S
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actives are present in plasma and tissue in the ewe for many weeks
after lambs are born. Like all ML compounds, the lipophylic nature
of moxidectin and abamectin results in a proportion of the
administered dose being excreted in the milk of lactating animals
(Alvinerie et al., 1996; Oukessou et al., 1999; Carceles et al., 2001;
Imperiale et al., 2004; Dupuy et al., 2008; Barrera et al., 2013)
and being detectable in the plasma of suckling offspring (Bogan and
McKellar, 1988; Alvinerie et al., 1996; Cerkvenik-Flajs et al., 2007).
This raises the possibility that treatment of ewes pre-lambing with
these long-acting products could result in sufﬁcient transfer of
active ingredient to the suckling lamb to result in anthelmintic
activity, and the potential for subsequent selection for ML-resistant
parasites in the lambs (Dever and Kahn, 2015). Here we describe a
study which was designed to test ﬁrstly for the transfer of mox-
idectin and abamectin from treated ewes into their lambs, and
secondly for the potential of any such transfer to select for ML-
resistance in Teladorsagia circumcincta.
2. Materials and methods
2.1. Experimental animals and design
Ninety mixed-age Romney ewes were selected on the basis of
ultrasound pregnancy scanning as being mated in the ﬁrst cycle
and carrying twin lambs. In the weeks prior to the start of the study
the ewes were preconditioned to a pelleted diet while still grazing
on pasture, in order to facilitate their transfer indoors. Ten days
prior to the expected date of ﬁrst lamb drop (Day 0) the ewes were
randomised into three groups of 30 based on liveweight (mean of
80.5 kg). Group 1 animals were then administered 1 mg/kg mox-
idectin by subcutaneous injection of a 2% solution (Cydectin long
acting injection for sheep, Zoetis New Zealand Ltd) at the base of
the ear, Group 2 animals were administered a CRC releasing 160mg
of abamectin, 4.62 g albendazole, 24 mg selenium and 120 mg
cobalt over approximately 100 days (Bionic, Merial NZ Ltd, Auck-
land New Zealand), while Group 3 animals remained untreated.
All ewes were then set-stocked for lambing, with all lambs being
tagged at birth so they could be identiﬁed to their mother, and
records were kept on which ewes gave birth each day. Seventeen
days after treatment 21 ewes, 7 from each treatment group, were
selected for uniformity of lambing day (±2 days from the mean
lambing date) and along with their twin lambs relocated indoors.
The 21 trial ewes were treated with albendazole at 4.75 mg/kg and
levamisole at 7.5 mg/kg to remove any existing worm burdens and
the effectiveness of this treatment was subsequently conﬁrmed by
faecal nematode egg count (FEC).
Animals were housed in a series of pens on rubber matted
ﬂooring over concrete. Each ewe and her lambswere fed twice daily
an allowance of 2.6 kg DM/day of a pelleted feed designed specif-
ically for lactating sheep (17.1% crude protein, 10.4 MJ ME/kg DM)
and 0.375 kg DM of a commercial baylage product (Fibre Pro).
Water was available ad lib throughout the experiment.
2.2. Sample collection and dosing of lambs
Both ewes and lambs were bled at intervals from the jugular
vein in order to measure the drug concentrations in plasma over
time (Table 1). Samples (approximately 7 ml) were collected into
heparinized vacutainer tubes, centrifuged at 2000 g for 20 min and
plasma pipetted into labelled vials and stored at 20 C until
analysis. At intervals, milk samples were collected from the ewes
for drug concentration analysis. These were collected by hand
milking ewes (that had brieﬂy been separated from their lambs),
into a clean 50ml container with an equal volume being taken fromeach half of the udder. Two subsamples (2 ml) were stored frozen
at 20 C until analysis.
Between four and 10 weeks after birth all lambs were dosed
weekly with 250 infective stage larvae (L3) of T. circumcincta. One
lamb from each pair was dosedwith L3 of a known drug susceptible
isolate (Wallaceville-11-susceptible) and the other was given L3
from a known ML-resistant isolate (SOL-ivm-resistant). The latter,
was isolated from sheep on a commercial farm in 1999, when the
efﬁcacy of ivermectin, abamectin and moxidectin against this
isolate was 42, 96 and >99%, respectively (Leathwick et al., 2000).
Since then, it has been maintained in the laboratory by passage in
lambs without further selection with anthelmintics. Towards the
end of the study lambs were sampled for FEC to determinewhether
infections had established and on days 80 and 84 post lambing all
lambs were euthanized and the abomasa collected for worm
counts. The same numbers of lambs from each treatment group
were euthanized at each kill date.2.3. Parasitology
FEC was determined using a modiﬁed McMaster method where
one egg counted equates to 17 eggs per g fresh faeces. Lambs were
euthanized by percussive stunning and exsanguination, and their
abomasa recovered. Abomasa were opened and repeatedly washed
before 10% aliquots of the washings were passed over a 38 mm sieve
and the number of nematodes recovered was enumerated.2.4. Determination of moxidectin levels in plasma
The levels of moxidectin in plasma were determined using the
method of Hughes et al. (2013). Brieﬂy,100 ml of thawed plasmawas
placed in a micro-centrifuge tube and 400 ml of cold acetonitrile
added to precipitate the protein. The sample was brieﬂy vortexed
and then centrifuged for 5 min at 12,000 rpm. A 200 ml aliquot of
the supernatant was transferred to an auto-sampler vial for sub-
sequent analysis using a liquid chromatography-triple quadrupole
mass spectrometry (LC-MS) system (TSQ Access Max, Thermo, New
Zealand). A 5 ml aliquot was injected onto a reverse-phase column
(SB-C8, 50  2.1 mm, 1.9 mm particle size, Agilent Technologies,
New Zealand) held at 25 C. Gradient elution with the following
HPLC solvents was performed with a ﬂow rate of 600 ml/min; sol-
vent A ¼ 0.1% formic acid in de-ionised water; solvent B ¼ 0.1%
formic acid in acetonitrile (LiChroSolvo grade, Merck, New
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4 min, then returned to 40% B over 30 s and re-equilibrated for 30 s,
for a total run time of 5 min.
Mass spectra were acquired using a heated electrospray ion-
isation probe at 400 C in positive ionisation mode, with the mass
spectrometer programmed to perform a selected reaction moni-
toring experiment for 640.3m/z as the parent ion and 498.3m/z and
528.3 m/z as the product ions.
2.5. Determination of moxidectin levels in milk
The moxidectin was extracted from milk with an approach
similar to Alvinerie et al. (1995), using solid phase extraction (SPE).
Proteinwas precipitated by adding 1ml of 4:1 acetonitrile:water (v/
v) to 1 ml of milk and sonicating the resulting mixture for 10 min.
The sample was then centrifuged for 5 min at 14,000 rpm, and
supernatant decanted and diluted with 2 ml of water. Diluted su-
pernatant was then loaded onto a preconditioned (2.5 ml methanol
followed by 2.5 ml water) SPE cartridge (Strata C18-E, 3 ml/100 mg,
Phenomenex, New Zealand). The cartridgewaswashedwith 1ml of
water followed by 1 ml of 3:1 water:methanol (v/v) and then
vacuum dried for 5 min, before eluting the moxidectin with 1.5 ml
methanol. The methanol eluent was then evaporated to dryness
under nitrogen, re-constituted with 0.5 ml acetonitrile and trans-
ferred into a 2 ml auto-sampler vial for analysis.
The concentration of moxidectin in milk was measured using
the LC-MS procedure described above for plasma. Moxidectin re-
covery from the milk was performed by spiking ﬁve 1 ml volumes
of milk were with either 10 or 40 ng of moxidectin. The spiked milk
was then thoroughly mixed and subjected to the above extraction
and analysis. The mean recovery was 70.7% ± 2.7%, similar to the
recoveries achieved by Alvinerie et al. (1995).
2.6. Determination of abamectin levels in plasma and milk
The plasma and milk concentrations of abamectin were deter-
mined using high-pressure liquid chromatography (HPLC) with
ﬂuorescence detection with modiﬁcations of methods described
previously (Alvinerie et al., 1995; Zele et al., 2010). Brieﬂy, 500 ml of
plasma or milk was placed in a micro-centrifuge tube, spiked with
500 ml of ivermectin standard (50 ng/ml in acetonitile) and 500 ml of
acetonitrile to precipitate the protein. The plasma sample was
thoroughlymixed with a vortexmixer, or in case of milk the sample
was sonicated for 1 min to ensure efﬁcient mixing of the internal
standard and sample matrices. The plasma or milk samples were
spiked with a further 400 ml of water to dilute the acetonitrile
content and then centrifuged for 3 min at 12,000 rpm. The super-
natant was then transferred to a pre-conditioned C18 SPE cartridge
and extracted as for moxidectin (above). The 1.5 ml methanol
eluent was placed into a 2 ml auto-sampler vial and dried under a
constant stream of nitrogen at 60 C to prepare for derivitization.
The derivitization procedure was as per Alvinerie et al. (1995),
where the dry residue was dissolved in 100 ml of freshly prepared
N-methylimidazole solution in acetonitrile (1:1 v/v). To initiate the
derivatization, 150 ml triﬂuoroacetic anhydride solution in aceto-
nitrile (1:2 v/v) was added and after brieﬂymixing the solutions for
completion of derivitization (<30s) the sample was transferred into
a 250 ml glass insert and placed back in the auto-sampler vial.
Analyses were performed using a HPLC system (Shimadzu
LC10ADvp, Shimadzu Oceania, New Zealand) equipped with a
ﬂuorescence detector. Samples were injected (10 ml) onto a reverse
phase HPLC column (C18 Luna, 150  3 mm, 3 mm particle size,
Phenomenex, New Zealand) held at 35 C. Gradient elutionwith the
following HPLC solvents was performed with a ﬂow rate of 500 ml/
min; solvent A ¼ 0.2% acetic acid in water; solventB ¼ methanol:acetonitrile (40:56 v/v) (LiChroSolv grade, Merck,
New Zealand). The gradient started at 80% B, increased to 100% B
over 15 min, then held for 9 min at 100% B and returned to 80% B
over 1 min before being re-equilibrated for 5 min, for a total run
time of 30 min. Detection was by ﬂuorescence, with the excitation
and emission wavelengths at 365 and 475 nm respectively.
Abamectin recovery from both the plasma and milk relative to
the internal standard ivermectin was performed by spiking ﬁve
500 ml volumes of plasma and milk with either 5 or 20 ng of aba-
mectin (equivalent to 10 and 40 ng/ml spikings). The spiked sam-
ples were thoroughly mixed and subjected to the above extraction
and analysis. The mean recovery of abamectin relative to the in-
ternal standard ivermectin was 103.4% ± 4.1% for plasma and
104.0% ± 5.3% for milk.2.7. Statistical analysis
No attempt was made to describe the plasma kinetics of mox-
idectin and abamectin (e.g. Cmax or AUC), as this was not the
purpose of the study and the number of samples collected were
inadequate for this purpose. Data are presented as means ± SEM.
Because of low counts and the number of zero values in FEC data
from the lambs, the mean FEC over four sampling occasions was
used for analysis. These numbers were transformed by Ln(x þ 1)
before analysis by 2-way ANOVA using a model which included
anthelmintic treatment (untreated, moxidectin or CRC), parasite
isolate (ML-resistant or esusceptible) and their interaction. The
effect of treatments to the ewes on the worm burdens of their
lambs was also assessed by 2-way ANOVA using the same model.
Where the F-test was signiﬁcant, an LSD (5%) was used to compare
treatments.3. Results
3.1. Drug concentrations in plasma and milk
Following treatment, moxidectin was present in all plasma
samples from ewes treated with this drug until about day 50 after
treatment (Fig. 1a) and in their lambs until about day 60 after
treatment (Fig. 1b). Although levels approached zero towards the
end of the sampling period the measured values were always
higher in the lambs than in the ewes (Fig. 1). Abamectin was pre-
sent in the plasma of all CRC-treated ewes, except in samples
collected before treatment, until the last sampling on day 80 after
treatment (Fig. 1c) and in the plasma of all their lambs until at least
day 60 after treatment (Fig. 1d). Neither drug was detected in the
plasma of ewes or lambs in the untreated control group. Seventeen
(±2) days after birth the concentration of moxidectin in the plasma
of the lambs was >15 times higher than in the ewes treated with
this drug (i.e. 15.5 vs 1.0 ng/ml in lambs and ewes, respectively,
Fig. 1a & b). In contrast, 17 days after birth the concentration of
abamectin in the plasma of the lambs was similar to that in the
ewes (1.78 and 1.68 ng/ml, respectively) and it subsequently
declined to levels lower than that in the ewes (Fig. 1c & d).
Anthelmintic actives, consistent with their respective treat-
ments, were present in the milk of all treated ewes from the ﬁrst
sample, 27 days after treatment, until the ﬁnal sample 80 days after
treatment (Fig. 2). For moxidectin, concentration declined from a
high initial level (>40 ng/ml) on day 27 to a low concentration on
day 80 (Fig. 2a). In contrast, the concentrations of abamectin inmilk
from CRC-treated ewes were lower (1e3 ng/ml) and did not show
any consistent trend over time (Fig. 2b).
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Fig. 1. The concentration of moxidectin (mean ± SEM) in the plasma of ewes treated with long-acting moxidectin a) and their lambs b) and the concentration of abamectin in the
plasma of ewes treated with a controlled release capsule containing abamectin and albendazole c) and their lambs d). Lambs were born on day 10 (±2).
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Fig. 2. The concentration (mean ± SEM) of moxidectin a) and abamectin b) in the milk of ewes treated prior to lambing with either a long-acting formulation of moxidectin or a
controlled release capsule containing abamectin and albendazole.
D.M. Leathwick et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 209e2142123.2. FEC and worm burdens in lambs
Although FEC was low in all lambs there were signiﬁcant dif-
ferences between the isolates and between the treatment groups
(Fig. 3a). Geometric mean FECs for the susceptible and resistant
isolates, averaged across treatments, were 3.8 and 2.0 epg,
respectively (p ¼ 0.047). Also, GM FEC for the different treatment
groups were 6.4, 2.4 and 1.4 epg for the untreated, CRC- and
moxidectin-treated groups respectively (p ¼ 0.006).
There was a signiﬁcant difference in infectivity between the two
isolates of T. circumcincta with worm burdens of the susceptible
isolate being signiﬁcantly greater than those of the resistant isolate
in the lambs from untreated ewes (means of 353 and 107 for the
susceptible and resistant isolates respectively, LSD ¼ 151, Fig. 3b).
There was no difference in the worm burdens of groups of lambs
infected with the resistant isolate indicating that treatment of their
dams had no effect on establishment of the resistant L3. However,
there was a signiﬁcant difference between the worm burdens of
lambs infected with the susceptible isolate in that lambs from
moxidectin-treated ewes had signiﬁcantly lower burdens thanthose from the other groups (means of 353, 73 and 306 for the
untreated, moxidectin-treated and CRC-treated groups respec-
tively, LSD ¼ 151, Fig. 3b).4. Discussion
This study had two aims; the ﬁrst to conﬁrm previous ﬁndings
regarding the transfer of ML anthelmintics intomilk (Carceles et al.,
2001; Dupuy et al., 2008; Barrera et al., 2013), and hence to the
suckling offspring (Alvinerie et al., 1996), in this case lambs (Bogan
and McKellar, 1988; Cerkvenik-Flajs et al., 2007); and the second to
test the hypothesis that the presence of transferred drug could
result in selection for anthelmintic resistant genotype nematodes
in the young lambs.
Moxidectin was present in both the plasma and milk of all ewes
treated with this active, and abamectin was present in the plasma
and milk of all ewes treated with a CRC, conﬁrming the results of
previous studies which demonstrated the transfer of ML actives
into the milk of lactating animals (Carceles et al., 2001; Imperiale
et al., 2004; Cerkvenik-Flajs et al., 2007). Further, the
Fig. 3. Geometric mean (backtransformed from Ln(x þ 1) scale) faecal nematode egg count (±SEM) (A) and mean worm burden (SEM) (B) in 10e12 week old lambs trickle dosed
with either an ML resistant or susceptible isolate of Teladorsagia circumcincta and whose mothers were either untreated or treated 10 (±2) days before birth with a long-acting
formulation of moxidectin or a controlled release capsule (CRC) containing abamectin and albendazole.
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centrations in plasma of the moxidectin-treated ewes for every
sampling date, a result similar to that of Imperiale et al. (2004) who
found moxidectin was present in milk at higher concentrations
than in plasma, until at least 35 days after treatment. However,
while those authors recorded a mean concentration in milk of
30.3 ng/ml 35 days after treatment withmoxidectin at 0.2mg/kg, in
this study a somewhat lower concentration of 16.7 ng/ml was
measured 32 days after treatment despite the administered dose
rate being 1mg/kg. Therefore, the levels of moxidectin measured in
milk in the current study were lower than might have been ex-
pected based on earlier studies. While it is unclear why this
occurred, it is possible that the administration of other anthel-
mintics on day 17 may have had an effect. Interactions between
anthelmintic classes, resulting in altered pharmacology, have been
recorded (Lanusse et al., 2015) and it is possible that such an
interaction, resulting from the administration of albendazole and
levamisole when the ewes were moved indoors, may have
contributed to the lower than expected levels of moxidectin
recorded here. However, moxidectin was measured in the plasma
of all lambs whose mothers were treated with this active until they
were at least 8 weeks old, conﬁrming the transfer of anthelmintic
active to suckling offspring inmilk demonstrated previously (Bogan
and McKellar, 1988; Carceles et al., 2001; Cerkvenik-Flajs et al.,
2007).
The concentrations of abamectin found in the plasma and milk
of the CRC-treated ewes was lower than the concentrations of
moxidectin found in the equivalent samples from moxidectin-
treated ewes, and the levels measured in samples of plasma and
milk from sheep treated with abamectin by subcutaneous injection
(Cerkvenik-Flajs et al., 2007). This is likely to reﬂect, at least in part,
the different delivery proﬁles of the CRC from that of subcutaneous
injection. While the CRC releases low levels of abamectin
(approximately 0.02 mg/kg liveweight per day) continuously over
about 100 days, administration by subcutaneous injection delivers
a single large dose on administration (Cerkvenik-Flajs et al., 2007).
Hence, it would be expected that the moxidectin treatment would
result in a high initial peak concentration in both plasma and milk,
followed by a protracted period of declining levels as the active is
excreted from the animal (Dupuy et al., 2007). In contrast, the slow
continuous release of abamectin would be expected to result in a
low but more constant level of active in plasma and milk. In both
cases, this is what was observed in the current study.
However, it has also been shown that the more lipophilic nature
of moxidectin results in amilk to plasma ratio greater than for other
ML actives (Oukessou et al., 1999; Imperiale et al., 2004; Cerkvenik-
Flajs et al., 2007; Dupuy et al., 2008; Barrera et al., 2013) with ahigher proportion of the total administered dose being recovered
from milk (Carceles et al., 2001; Imperiale et al., 2004). This was
seen here in the samples taken 27 days after treatment, when the
concentration of moxidectin in the ewe's milk and plasmawas 43.8
and 1.03 ng/ml, respectively, a milk to plasma ratio of 42.5. In
contrast, the equivalent concentrations of abamectin were 1.78 and
2.42 ng/ml for plasma and milk, respectively, a ratio of 1.4. This
difference in afﬁnity for milk undoubtedly contributed to the
higher concentrations of moxidectin (15.5 ng/ml) found in the
plasma of lambs whose mothers were treated with this drug, than
the levels of abamectin (1.7 ng/ml) in lambs from ewes treatedwith
a CRC. Our results are, therefore, consistent with earlier studies in
that moxidectin concentrations tended to be considerably higher in
milk than in plasma (Imperiale et al., 2004), whereas abamectin
concentrations in milk and plasma tended to be similar (Cerkvenik-
Flajs et al., 2007).
It follows then, that the nature of the different actives and their
delivery proﬁle in the different products resulted in the different
concentration proﬁles in the plasma of the young lambs i.e. lambs
whose mothers were treated with moxidectin showed higher
initial levels in plasma than the lambs whose mothers were treated
with a CRC. In both cases plasma concentrations declined over time,
but in those lambs from moxidectin-treated ewes the rate of
decline was faster i.e. from 15.5 ng/ml on day 27 to 0.98 ng/ml on
day 52 for lambs from moxidectin-treated ewes, compared to
1.68 ng/ml on day 27 to 0.32 ng/ml on day 52 for lambs from the
CRC-treated ewes. A faster decline would be consistent with
declining plasma and milk concentrations in the moxidectin-
treated ewes relative to the more constant levels in the CRC-
treated ewes. Plasma concentrations for both groups of lambs
would also be expected to decline as the lambs gotolder, larger and
their milk intake declined.
The second aim of the study was to determine whether this
transfer of active to young lambs in the ewe's milk has the potential
to confer an advantage to resistant genotype nematodes i.e. to
select for anthelmintic resistance. Lambs, from ewes treated with
moxidectin, which were trickle-dosed with infective larvae of
susceptible genotype T. circumcincta had lower worm burdens (by
70%) at slaughter than lambs from the other treatment groups
which were dosed with the same isolate. In contrast, all lambs
trickle-dosed with the resistant isolate of T. circumcincta had
similar worm burdens at slaughter. Therefore, pre-lambing treat-
ment of ewes with moxidectin injection resulted in reduced
establishment of susceptible, but not resistant, T. circumcincta in the
lambs as a result of transfer of active in the ewe's milk. Such a
disparity did not occur when ewes were treated with a CRC con-
taining abamectin, presumably because the levels of abamectin
D.M. Leathwick et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 209e214214reaching the suckling lamb were insufﬁcient to have an effect on
establishment of the susceptible genotype L3. This probably reﬂects
the delivery proﬁle of the CRC and less lipophilic nature of aba-
mectin compared with moxidectin, described above, which
combine to give lower concentrations of abamectin than mox-
idectin in the ewe's milk. Therefore, we accept the hypothesis that
the presence of moxidectin, transferred in the milk from ewes
treated pre-lambing, can result in selection for anthelmintic resis-
tant genotype nematodes in the young lambs. However, we ﬁnd no
evidence to support the equivalent hypothesis with respect to
treatment with a CRC containing abamectin.
It has long been recognized that treatment of pregnant ewes in
the period immediately before or after lambing has the potential to
accelerate the development of anthelmintic resistance (Dash et al.,
1985; Michel, 1985). The mechanism for this was perceived to be
that an anthelmintic treatment at this time would pre-select for
resistance an important source of worm infection in the lambs. In a
later modelling study, Leathwick et al. (1995) added that a treat-
ment at this time also effectively eliminated a potentially important
source of unselected genotypes i.e. worms in ‘refugia’ (Van Wyk,
2001). The use of long-acting anthelmintics added an additional
potential mechanism for selection of resistance, that of ‘tail’ se-
lection (le Jambre et al., 1999; Leathwick and Besier, 2014). A large
scale replicated ﬁeld study in New Zealand conﬁrmed the potential
of a pre-lambing treatment of ewes with a CRC containing alben-
dazole to accelerate the development of resistance to benzimid-
azole anthelmintics (Leathwick et al., 2006). Albendazole CRC, such
as the ones used in that study, have no withholding periods for
meat or milk (Chartier et al., 1996; http://www.merial.co.nz/Sheep/
Products/Pages/extender_seco.aspx), reﬂecting the fact that
albendazole does not transfer into milk of treated lactating animals
to the extent that ML actives do (De Liguoro et al., 1996; Dever and
Kahn, 2015), and so the mechanism of resistance selection in that
study must have involved only effects against worms in the ewe.
Therefore, the process of selection demonstrated here (i.e. selection
for resistant worms in the lamb via transfer of drug in the ewe's
milk) represents a new, and until recently unconsidered (Dever and
Kahn, 2015), pathway by which use of moxidectin injection in
lactating ewes could select for resistance. The results of this study,
therefore, represent yet another reason why administration of
long-acting anthelmintic products to pre-lambing ewes must be
considered high-risk for selecting anthelmintic resistance and their
use approached with caution.
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